The move raises privacy concerns as the drugmaker takes control of the genetic data of millions of clients of the once-sizzling DNA-testing startup.
23andMe sells gene-testing business to DNA drug maker Regeneron
Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.
LA Times
•
41 minutes ago
Regeneron Pharmaceuticals to pay $256 million for 23andMe in bankruptcy sale - UPI.com
AMD to sell ZT Systems' manufacturing business to Sanmina in $3 billion deal
23andMe Sold To Biotechnology Company For $256 Million
Nvidia stock wavers as market turmoil eclipses AI chip announcements
Regeneron Buys 23andMe in Bankruptcy Auction
Coinbase stock officially joins S&P 500, cementing milestone for company and crypto industry
L'azienda farmaceutica statunitense Regeneron acquisterà l'azienda di test genetici 23andMe - Il Post
Qorvo nominates Starboard's Peter Feld to board, ends boardroom battle
Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy…
Chipmaker AMD agreed on Monday to sell the data center infrastructure manufacturing business of recently acquired ZT Systems to…
The acquisition comes two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
Nvidia stock pared losses Monday as market turmoil overshadowed AI chip news during the Computex Taipei tech expo.
Anne Wojcicki made $305m bid for firm, which has lost customers since declaring bankruptcy, with backing of Fortune 500 company
The possible sale of 23andMe’s genetic data could set a precedent for future cases where companies look to offload increasingly…
